You are here

  • Home
  • Archive
  • Volume 81, Issue 6
  • Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease

Article Text

Article menu

Download PDFPDF

Correspondence
Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease
Free
  1. Piero Ruscitti1,
  2. Tanja A Stamm2,
  3. Roberto Giacomelli1
  1. 1 Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila, Abruzzo, Italy
  2. 2 Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent System, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Dr Roberto Giacomelli, Department of Clinical Sciences and Applied Biotechnology, University of L'Aquila, L'Aquila 67100, Abruzzo, Italy; roberto.giacomelli{at}cc.univaq.it

https://doi.org/10.1136/annrheumdis-2020-218032

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article by Kedor et al 1 on the efficacy of canakinumab, an interleukin (IL)−1β antagonist, on patients with adult-onset Still’s disease (AOSD). In this multicentre, double-blind, randomised, placebo-controlled trial, 36 patients with active joint involvement were enrolled1; this is the largest clinical trial performed on AOSD so far. Moreover, the results of this trial are of considerable interest in this field, considering the challenge of arranging prospective studies on a rare disease. Despite the improvement of many articular secondary measures, the primary outcome, the proportion of patients with a clinically relevant reduction of the articular manifestation measured by change in disease activity score (ΔDAS28(ESR) >1.2) at week 12, did not achieve statistical significance.1 Apparently, this finding seems to be in contrast with the strong scientific rationale, which is behind the study, of inhibiting IL-1β in AOSD and with the confirmed efficacy of canakinumab reported …

    View Full Text

    Linked Articles